Clinical Trials
- All
- Analytical Services
- Bioanalytical Services
- Bioassay Development
- Biologics, Proteins, Vaccines
- Biosimilars
- Chemistry
- Clinical Trials
- Drug Delivery
- Drug Development
- Drug Discovery
- Formulation Development
- Information Technology
- Laboratory Testing
- Methods Development
- Microbiology
- Preclinical Outsourcing
- R&D
- Toxicology
-
Bio News | Clinical Trials | Drug Development | Industry News | R&D | Trials & Filings
JHL Biotech Receives NMPA Approval
For Phase I & Phase III clinical trial applications for a proposed bevacizumab biosimilar, JHL1149, to treat forms of cancer10.15.18
-
Bio News | Clinical Trials | Drug Discovery | Industry News | R&D
Almac Adds Illumina NovaSeq 6000
The sequencer aims to benefit Biopharma clients’ biomarker discovery and clinical trial projects10.12.18
-
Biologics, Proteins, Vaccines | Clinical Trials
Getting to First-in-Human Clinical Trials
A make-or-break milestone for small biopharmasDavid Kenyon, Patheon 10.10.18
-
Clinical Trials | R&D
Improving Pharma R&D Efficiency: The need to transform clinical trials
Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if tICON plc 10.10.18
-
Breaking News | Clinical Trials | CRO News | Drug Development | Information Technology
PAREXEL, Datavant in RWE Alliance
Aims to link healthcare data from a variety of real-world and clinical study data sources to improve drug development09.17.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D | Trials & Filings
Boehringer Announces Positive Phase III Results
Confirmed that Cyltezo is equivalent to Humira, with no clinically meaningful differences in efficacy or safety09.12.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Trials & Filings
FDA Grants Amgen & AstraZeneca Breakthrough Therapy Designation
For tezepelumab in patients with severe asthma without an eosinophilic phenotype09.07.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Discovery | Industry News | R&D | Trials & Filings
Gilead, Galapagos Announce Positive Phase 2 Results
In the TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor for the treatment of ankylosing spondylitis09.06.18
-
Clinical Trials | CRO News | Drug Development | Information Technology
-
Bio News | Clinical Trials | Industry News | Promotions & Moves
Altasciences Appoints Clinical Trial Consultant
Dr. William J. Foster, MD, PhD, FRCSC is a practicing retinal physician in Montreal, Canada09.06.18
-
cGMP Manufacture | Clinical Trial Materials | Clinical Trials | Drug Development
Integrating CDMO and CRO Services
Mark Egerton explains the importance of integrating formulation development and adaptive manufacturing with clinical researchOnline Exclusives Kristin Brooks, Managing Editor 09.04.18
-
Analytical Services | Bio News | Breaking News | Clinical Trials | Collaborations & Alliances | Industry News | Information Technology | Trials & Filings
CRF's TrialMax Slate Chosen for Phase III Study
The large-scale prostate cancer trial will involve up to 1000 screened patients across 75+ sites and 10+ countries08.30.18
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Industry News
Sirona Biochem Receives $500,000 Milestone from Wanbang
CFDA approves Phase I clinical trial for Sirona's SGLT-2 inhibitor08.29.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Innovate, Amarex Sign Agreement
To provide data management and biostatistics for its planned Phase 3 celiac disease trial08.23.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Rexahn, Merck Partner for Cancer
To evaluate the combination of RX-5902 and Merck’s KEYTRUDA® in a Phase 2 trial in patients with TNBC08.21.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Industry News
Agenus Receives Second Milestone from Merck
Merck initiated a Phase I clinical trial of an antibody candidate discovered by Agenus, sparking a $4M milestone payment08.20.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Natera, Fox Chase Cancer Center Partner for Oncology
To assess Signatera™ (Research-Use Only) customized circulating tumor DNA assay for recurrence monitoring of kidney cancer08.20.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Discovery | Industry News | R&D
Agenus Receives Merck Milestone
After Merck's initiation of a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus08.16.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Industry News | R&D
Altasciences Acquires SNBL's Preclinical Testing Business
Will add comprehensive preclinical safety testing services to Altasciences’ full service clinical and bioanalytical offerings08.15.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
Mustang Bio, St. Jude Partner for X-SCID
Most common form of severe combined immunodeficiency, affecting approximately one in 50,000 to 100,000 newborns worldwide08.13.18
